If you’re into biotech stock opportunities, you know the sector has been suppressed lately:
XBI, a broad-based biotech ETF
That’s due to some macro factors – including the ability to find patients and the costs of the trials.
Now that …
If you’re into biotech stock opportunities, you know the sector has been suppressed lately:
XBI, a broad-based biotech ETF
That’s due to some macro factors – including the ability to find patients and the costs of the trials.
Now that …
It was a warm Miami morning, and we were wheels up.
We were taking the plane 30 minutes north, landing directly inside of Kennedy Space …
A couple months ago, I was invited to Palm Beach for the “Free Speech Investment Summit.”
It was an opportunity to do a “deep dive” into the company Truth Social. I got to speak with the company’s leadership, interview the …
Here we go again… another month, another hit piece on Nancy Pelosi, her family, and her trades.
The Department of Justice recently announced an antitrust lawsuit against Visa, causing the stock to careen lower from $288 to $268.
To me, …
At the beginning of August, the market crashed:
It’s been well dissected, but the basic idea was this:
The Bank of Japan decided to hike rates while U.S. data came in soft. This led to a massive unwind in multiple …
Gold has been a solid performing asset class this year:
It’s up nearly 30% year-to-date.
Gold investors have been bidding up the shiny metal in anticipation of the Federal Reserve easing policy by way of rate cuts.
It’s a trade …